Download PDF

1. Company Snapshot

1.a. Company Description

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States.Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer.


As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York.The company was founded in 1981 and is headquartered in Los Angeles, California.

Show Full description

1.b. Last Insights on RDNT

RadNet, Inc.'s recent performance was negatively impacted by a short seller report released by Hunterbrook Capital, questioning the company's AI hype and growth claims. Additionally, several institutional investors, including New York State Common Retirement Fund, Emerald Advisers LLC, and Texas Permanent School Fund Corp, reduced their stakes in the company. Despite beating Q4 earnings estimates, concerns around key metrics and year-ago comparisons may have tempered investor enthusiasm. The company's acquisition strategy, including the purchase of GLEAMER SAS, may also be under scrutiny.

1.c. Company Highlights

2. RadNet's Strong Q4 2025 Earnings: A Leap Forward in Digital Health

RadNet, Inc.'s fourth quarter 2025 revenue surged 14.8% to $547.7 million, with adjusted EBITDA increasing 16.9% to $87.7 million. The company's Digital Health revenue grew an impressive 48.2% to $27.9 million, with adjusted EBITDA of $4.9 million. Earnings per share (EPS) came out at $0.862, significantly beating estimates of $0.19. The company's imaging center procedural volume growth was robust, with aggregate growth at 14.1% and same-center advanced imaging growth at 9.6%.

Publication Date: Mar -03

📋 Highlights
  • Revenue and EBITDA Growth: Q4 2025 revenue rose 14.8% to $547.7M; adjusted EBITDA increased 16.9% to $87.7M.
  • Digital Health Expansion: Digital Health revenue surged 48.2% to $27.9M, with ARR of $75.4M in 2025 and $140M target by 2026.
  • Gleamer Acquisition Impact: Adds $30M ARR in 2026, 700+ customer contracts, and accelerates DeepHealth’s global AI leadership in radiology.
  • Strategic Expansion: Plans to open 11–13 new centers in 2026, plus $120M revenue boost from Indiana/Southwest Florida acquisitions.
  • Financial Strength and Guidance: $776M cash balance; 2026 Imaging Center revenue growth of 17–19%, with EBITDA margin improvements expected via AI integration.

Operational Highlights

RadNet, Inc. opened seven de novo facilities in 2025 and expanded several joint venture partnerships, demonstrating its commitment to growth. The company also acquired several imaging facilities and iCAD, C-MODE, and CMAR, which have been integrated into the DeepHealth product portfolio. The acquisition of Gleamer, a Paris-based radiology AI company, is expected to add approximately $30 million of Annual Recurring Revenue (ARR) in 2026 and accelerate DeepHealth's global trajectory.

Digital Health Growth

The company's Digital Health revenue is anticipated to grow 45-55% in 2026, driven by sales of AI-powered workflow and clinical solutions. The introduction of the new metric, Annual Recurring Revenue (ARR), was $75.4 million at December 31, 2025, and is expected to reach $140 million by the end of 2026. The acquisition of Gleamer is expected to contribute significantly to ARR, with the combined company becoming the largest provider of radiology clinical AI solutions worldwide.

Valuation and Outlook

RadNet's valuation metrics indicate a premium, with a P/E Ratio of 120.92, P/S Ratio of 2.85, and EV/EBITDA of 27.22. The company's leverage ratio is expected to be slightly less than 2 times after completing the Gleamer acquisition. Analysts estimate next year's revenue growth at 10.3%. The company's guidance for 2026 indicates significant growth, driven by same-center performance, tuck-in acquisitions, and de novo center openings.

Margin Expansion

The Digital Health business is expected to see improved margins in the mid-to-long term, driven by organic growth and investments in new product development. The company expects significant efficiencies in X-ray volume and plans to recover costs to make radiologists' time more available for advanced imaging studies. The EBITDA guidance assumes a $5 million EBITDA loss from Gleamer in 2026, with expectations to turn EBITDA positive by 2027.

3. NewsRoom

Card image cap

RadNet Insider Sells 15,000 Shares as Stock Falls 12% in 2026

Mar -23

Source: fool.com

Card image cap

RadNet CFO Touts “Unprecedented” Volume Momentum, Sees Digital Health as 2026 Growth Engine

Mar -23

Source: defenseworld.net

Card image cap

RadNet, Inc. (RDNT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar -12

Source: seekingalpha.com

Card image cap

RadNet's Pullback Offers Upside With Outpatient Imaging And AI

Mar -07

Source: seekingalpha.com

Card image cap

RadNet, Inc. (RDNT) GLEAMER SAS - M&A Call Transcript

Mar -05

Source: seekingalpha.com

Card image cap

RadNet, Inc. Reminds Investors of the Dedicated Conference Call and Presentation About the Recently Completed Acquisition of Gleamer SAS

Mar -04

Source: globenewswire.com

Card image cap

Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes

Mar -03

Source: prnewswire.com

Card image cap

Baron Health Care Fund Q4 2025 Contributors And Detractors

Mar -03

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (6.01%)

6. Segments

Imaging Centers

Expected Growth: 6%

RadNet's Imaging Centers segment growth is driven by increasing demand for outpatient imaging services, strategic acquisitions, and expansion of existing centers. Additionally, the company's focus on value-based care and cost-effective solutions resonates with payers and patients, leading to increased market share and revenue growth.

Artificial Intelligence

Expected Growth: 8%

RadNet's AI segment growth is driven by increasing adoption in medical imaging, expanding applications in healthcare analytics, and strategic partnerships. Additionally, the company's investments in AI-powered diagnostic tools, such as image recognition and predictive analytics, are contributing to its growth. Furthermore, the growing demand for precision medicine and personalized healthcare is also fueling the segment's growth.

7. Detailed Products

Imaging Centers

RadNet operates a network of outpatient imaging centers that provide a range of diagnostic imaging services, including MRI, CT, PET, and X-ray scans.

Teleradiology Services

RadNet provides teleradiology services, allowing radiologists to remotely interpret medical images and provide diagnostic reports to healthcare providers.

Artificial Intelligence (AI) Solutions

RadNet develops and deploys AI-powered solutions to improve the accuracy and efficiency of medical imaging diagnoses.

Radiology Information Systems (RIS)

RadNet offers RIS software to manage medical imaging data, streamline workflows, and improve patient care.

Consulting and Advisory Services

RadNet provides consulting and advisory services to help healthcare providers optimize their medical imaging operations and improve patient care.

8. RadNet, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

RadNet, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the emergence of new technologies and competitors.

Bargaining Power Of Customers

RadNet, Inc.'s customers have limited bargaining power due to the company's strong market position and the lack of alternative providers.

Bargaining Power Of Suppliers

RadNet, Inc. relies on a few key suppliers for its medical imaging equipment, giving them some bargaining power, but the company's size and market position mitigate this threat.

Threat Of New Entrants

The threat of new entrants is low due to the high barriers to entry in the medical imaging industry, including the need for significant capital investment and regulatory compliance.

Intensity Of Rivalry

The medical imaging industry is highly competitive, with several established players competing for market share, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 58.42%
Debt Cost 5.53%
Equity Weight 41.58%
Equity Cost 12.37%
WACC 8.38%
Leverage 140.48%

11. Quality Control: RadNet, Inc. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Natera

A-Score: 4.7/10

Value: 4.0

Growth: 7.0

Quality: 3.6

Yield: 0.0

Momentum: 8.5

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Waters

A-Score: 4.4/10

Value: 1.0

Growth: 5.2

Quality: 7.7

Yield: 0.0

Momentum: 6.0

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
Exact Sciences

A-Score: 4.4/10

Value: 4.4

Growth: 6.0

Quality: 3.5

Yield: 0.0

Momentum: 9.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Twist Bioscience

A-Score: 3.8/10

Value: 6.8

Growth: 7.1

Quality: 4.6

Yield: 0.0

Momentum: 2.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
RadNet

A-Score: 3.5/10

Value: 3.6

Growth: 3.9

Quality: 2.7

Yield: 0.0

Momentum: 6.0

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Charles River Laboratories

A-Score: 3.3/10

Value: 4.6

Growth: 4.1

Quality: 3.1

Yield: 0.0

Momentum: 3.5

Volatility: 4.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

57.83$

Current Price

57.83$

Potential

-0.00%

Expected Cash-Flows